左卡尼汀联合促红细胞生成素治疗肾性贫血的疗效.docVIP

左卡尼汀联合促红细胞生成素治疗肾性贫血的疗效 ［ ］目的探讨对肾性贫血患者行左卡尼汀 +促红细胞生成素联合治疗的临床效果。方法将 2015年6月?2016年6月我院收治的84例肾性贫血 患者作为研宄对象，根据数字随机表法分为联合组和 单一组，各42例。单一组行促红细胞生成素治疗，联 合组则行促红细胞生成素+左卡尼汀联合治疗，观察并 比较两组治疗效果、血液相关指标以及不良反应发生 率。结果联合组治疗有效率（92.86%）显著高于单 一组（73.81%），联合组不良反应发生几率（11.90%） 显著低于单一组（33.33°/。），联合组血红蛋白（Hb） 以及血细胞比容（Het）均高于单一组，差异均有统计 学意义（P ［关键词］左卡尼汀；促红细胞生成素；肾性贫血 患者；血液指标 ［ ］R556 ［ ］B ［ ］ 1673-9701 （2017） 08-0119-03 ［Abstract］ Objective To investigate the clinical effect of L-carnitine combined with erythropoietin in patients with renal anemia. Methods A total of 84 patients with renal anemia treated in our hospital from June 2015 to June 2016 were enrolled and divided into combination group and single group according to the random number table method，with 42 cases in each group. The single group was given erythropoietin treatment, and the combination group was treated with erythropoietin and L-carnitine. The treatment effect, blood related indices and the rate of adverse reactions between the two groups were observed and compared. Results The effective rate was 92.86% in the combination group, significantly higher than that in the single group (73.81%) . The incidence of adverse reactions was 11.90% in the combination group， significantly lower than that in the single group (33.33%). The hemoglobin (Hb) and hematocrit (Het) in the combination group were higher than those of the single group, the differences were statistically significant for all (P2 年时 间；②患者在接受血液透析治疗期间并未出现感染、 溶血以及输血情况;③患者均为每周接受2?3次规律 性透析治疗。排除标准：①合并恶性肿瘤者；②接受 研究前有血管紧张素抑制剂用药史者；③合并明显心 力衰竭以及高血压病者；④合并严重的甲状旁腺功能 亢进者。经统计学检验，两组患者的基本资料及病情 程度差异无统计学意义（P＞0.05）,具有可比性。 1.2治疗方法 单一组行促红细胞生成素（生产厂家：Roche Diagnostics GmbH 批准文号：治疗，每次 注射80?120U/kg，每周2?3次，同时，服用叶酸、 铁剂以及VitB12进行辅助治疗。12周为1个疗程。 联合组则行促红细胞生成素+左卡尼汀（生产厂家: Sigma-Tan Industrie Farmaceutiche Riunite S.p.A. ft匕准 文号：联合治疗，患者透析结束后，在 20 mL生理盐水中加入1.0 g左卡尼汀，行静脉推注， 每周2?3次。12周为1个疗程。除此之外，在联合 组接受治疗的过程中，需要密切监测患者血红蛋白以 及红细胞压积水平，当红细胞压积＞33%或者血红蛋 白＞100g/L时，则需要根据患者的实际情况，减少促 红细胞生成素的使用剂量，每间隔4周根据患者的临